Exclusive: Albireo Pharma, Inc. Stock Price Hits 52-Week High Today

Exclusive: Albireo Pharma, Inc. Stock Price Hits 52 Week High Today

The stock of Albireo Pharma, Inc. (NASDAQ:ALBO) hit a new 52-week high and has $58.41 target or 98.00% above today’s $29.50 share price. The 7 months bullish chart indicates low risk for the $55.60 million company. The 1-year high was reported on Nov, 21 by Barchart.com. If the $58.41 price target is reached, the company will be worth $54.49 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 46,645 shares traded hands or 32.69% up from the average. Albireo Pharma, Inc. (NASDAQ:ALBO) has risen 111.38% since April 19, 2016 and is uptrending. It has outperformed by 107.52% the S&P500.

According to Zacks Investment Research, “Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States.”

More recent Albireo Pharma, Inc. (NASDAQ:ALBO) news were published by: Quotes.Wsj.com which released: “News Albireo Pharma Inc.ALBO” on November 03, 2016. Also Streetinsider.com published the news titled: “Form 3 ALBIREO PHARMA, INC. For: Nov 03 Filed by: Sermon Charles” on November 07, 2016. Marketwired.com‘s news article titled: “Biodel Inc. and Albireo Limited Agree to Combine” with publication date: May 25, 2016 was also an interesting one.

ALBO Company Profile

Albireo Pharma, Inc., formerly Biodel Inc., incorporated on December 8, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company’s clinical pipeline includes over two Phase II product candidates and one Phase III product candidate. The Company’s pipeline includes A4250, A3384 and Elobixibat.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags:

Leave a Comment